CincyTech Bucks Economic Trends, Reports Record Year of Investments and Activity

For CincyTech and its portfolio companies, 2022 was bookended by the strong performance that belied that of the national economy.

Consider: In January, Enable Injections announced a $215 million Series C financing that has resulted in more local manufacturing jobs and capacity for the maker of Enfuse, a wearable delivery device that replaces IV infusion for at-home use.

In December, the founders of Genetesis – Peeyush Shrivastava, Vineet Erasala and Manny Setegn – were named to the prestigious Forbes “30 under 30” list in healthcare.

Earlier in 2022, Genetesis closed $17.5 million in Series C financing, led by notable investors Mithril Capital with participation from Cercano Management, and Genetesis expanded the number of hospitals testing Cardioflux, its diagnostic imaging platform that rapidly detects cardiovascular disease.

“My co-founders and I are thrilled to be included on the Forbes 30 under 30 list in Healthcare this year. We have a long way to go in realizing the true mission we hold near and dear here at Genetesis,” said co-founder Peeyush Shrivastava, a graduate of Mason High School and a 2017 Thiel Fellowship awardee. “We are especially thankful for our Mason/Cincinnati community that has been a part of our growth and journey since Day One.”

For the year, CincyTech experienced a record $391 million in co-investment in its portfolio companies.

CincyTech also added two key team members in finance and life sciences. Kerry Hull, Vice President of Finance, joined the team from PricewaterhouseCoopers (PwC), where she was a senior manager in the asset management practice. Christin Godale, Ph.D., joined the team as Director of Life Sciences after completing her Ph.D. in Neuroscience at the University of Cincinnati.